Clinical Trial Details
| Trial ID: | L4725 |
| Source ID: | NCT03784703 |
| Associated Drug: | Atorvastatin 40 Mg Oral Tablet |
| Title: | Type 2 Diabetic Patients Maintained on Statin Therapy |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Dyslipidemia Associated With Type II Diabetes Mellitus |
| Interventions: | DRUG: Atorvastatin 40 Mg Oral Tablet|DRUG: Rosuvastatin 10 Mg Oral Tablet |
| Outcome Measures: | Primary: hs-CRP (pg/mL), biomarkers that linking the inflammatory hypothesis with diabetes mellitus and atherosclerosis., 6 months|sortilin (ng/mL), Serum Level, 6 months|adiponectin (ng/mL), Serum Level, 6 months|leptin (ng/mL), Serum Level, 6 months | Secondary: glucose level, fasting blood glucose (FBG) (mg/mL), 6 months|glycated hemoglobin, glycated hemoglobin (Hb A1c%), 6 months|total cholesterol, TCH: total cholesterol (mg/dL), 6 months|low density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol (mg/dL), HDL-C: high density lipoprotein-cholesterol (mg/dL); Triglycerides (mg/dL)., 6 months|high density lipoprotein-cholesterol, HDL-C: high density lipoprotein-cholesterol (mg/dL); Triglycerides (mg/dL)., 6 months|Triglycerides, Triglycerides (mg/dL)., 6 months |
| Sponsor/Collaborators: | Sponsor: Damanhour University | Collaborators: Tanta University |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 160 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION |
| Start Date: | 2018-01-01 |
| Completion Date: | 2020-01-31 |
| Results First Posted: | |
| Last Update Posted: | 2021-01-05 |
| Locations: | Tanta University Hospital, Tanta, El-Gharbia, 31527, Egypt |
| URL: | https://clinicaltrials.gov/show/NCT03784703 |
